Search results for "DISEASE PROGRESSION"

showing 10 items of 835 documents

Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized pha…

2017

Abstract Objectives To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA). Materials and Methods Karnofsky Performance Status (KPS) and GA as clinical parameters, and prognostic inflammatory and nutritional index (PINI), and Glasgow prognostic score (GPS) as biomarkers were analyzed for association with clinical outcome within the randomized phase III PEg-LIposomal Doxorubicin vs. CApecitabin iN MBC (PELICAN) trial of first-line pegylated liposomal doxorubicin (PLD) or capecitabine. Results Of 210 patients, 38% were > 65 years old. GA (n = 152) classified 74% as…

0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisAnthracyclinemedicine.medical_treatmentBreast NeoplasmsPolyethylene GlycolsCapecitabine03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansDoxorubicinKarnofsky Performance StatusGeriatric AssessmentCapecitabineAgedChemotherapyFrailtybusiness.industryAge FactorsGeriatric assessmentMiddle Agedmedicine.diseaseMetastatic breast cancer030104 developmental biologyTreatment OutcomeOncologyDoxorubicin030220 oncology & carcinogenesisDisease ProgressionBiomarker (medicine)FemaleGeriatrics and GerontologybusinessBiomarkersmedicine.drugJournal of geriatric oncology
researchProduct

Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role…

2016

// Simona Taverna 1,2,* , Marco Giallombardo 1,3,* , Ignacio Gil-Bazo 4 , Anna Paola Carreca 3 , Marta Castiglia 3 , Jorge Chacartegui 3 , Antonio Araujo 5 , Riccardo Alessandro 1,2 , Patrick Pauwels 6 , Marc Peeters 7 and Christian Rolfo 3 1 Department of Biopathology and Medical Biotechnology, Section of Biology and Genetics, University of Palermo, Palermo, Italy 2 Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo, Italy 3 Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital (UZA) and Center for Oncological Research (CORE) Antwerp University, Wilrijkstraat, Edegem, Antwerp, Belgium 4 Department of Oncology, Clinica…

0301 basic medicineOncologymedicine.medical_specialtyPediatricsLung NeoplasmsReviewDiseaseexosomesNSCLCMetastasis03 medical and health sciencesliquid biopsies0302 clinical medicineSettore BIO/13 - Biologia ApplicataCarcinoma Non-Small-Cell LungInternal medicineBiomarkers TumorTumor MicroenvironmentmedicineHumansexosomeLung cancerBiologySurvival rateTumor microenvironmentbusiness.industryMolecular pathologyCancerbiomarkersPrognosismedicine.disease3. Good healthrespiratory tract diseasesmicroRNAsGene Expression Regulation Neoplastic030104 developmental biologyOncologyTumor progressionexosomes; NSCLC; liquid biopsies; biomarkers; microRNAs030220 oncology & carcinogenesisDisease ProgressionbiomarkerHuman medicinebusinessliquid biopsie
researchProduct

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

2014

Abstract Background Trastuzumab emtansine (T-DM1), a new agent developed for the treatment of HER2-positive breast cancer, is an antibody-drug conjugate with a complex compound obtained by the conjugation of trastuzumab, a stable thioether linker, and the potent cytotoxic drug maytansine-derivate(DM1), which inhibits cell division and induces cell death. Field of study PubMed database, ESMO, ASCO, San Antonio Breast Cancer Symposium Meeting abstracts and clinicaltrials.gov were searched using the terms “Anti-HER2 treatment breast cancer and trastuzumab emtansine (T-DM1) “; papers considered relevant for the aim of this review were selected. Findings/results The phase I trials have determine…

0301 basic medicineOncologymedicine.medical_specialtyReceptor ErbB-2Antineoplastic AgentsBreast NeoplasmsAdo-Trastuzumab EmtansineAntibodies Monoclonal Humanized03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerTrastuzumabInternal medicineHumansMedicineMaytansineProgression-free survivalNeoplasm Metastasisskin and connective tissue diseasesTaxanebusiness.industryCancerHematologyTrastuzumabmedicine.diseaseMetastatic breast cancerClinical trial030104 developmental biologyClinical Trials Phase III as TopicOncologychemistryTrastuzumab emtansine030220 oncology & carcinogenesisDisease ProgressionFemaleNeoplasm Recurrence Localbusinessmedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation

2016

// Nicoletta Staropoli 1, * , Domenico Ciliberto 1, * , Silvia Chiellino 1 , Francesca Caglioti 1 , Teresa Del Giudice 1 , Simona Gualtieri 1 , Angela Salvino 1 , Alessandra Strangio 1 , Cirino Botta 1 , Sandro Pignata 2 , Pierfrancesco Tassone 1, * , Pierosandro Tagliaferri 1, * 1 Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy 2 Department of Gynecologic and Urologic Oncology, Fondazione Pascale, National Cancer Institute of Naples, Naples, Italy * These authors have contributed equally to this work Correspondence to: Pierosandro Tagliaferri, email: tagliaferri@unicz.it Keywords: ovarian cancer, targeted therapy, systemic chemotherapy, systemat…

0301 basic medicineOncologymedicine.medical_specialtyTime FactorsBevacizumabmedicine.medical_treatmentAngiogenesis InhibitorsDisease-Free SurvivalTargeted therapyTargeted therapy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsOvarian cancerInternal medicineBiomarkers TumorOdds RatiomedicineHumansMeta-analysiMolecular Targeted TherapyPrecision MedicineSystemic chemotherapyOvarian Neoplasmsbusiness.industryPatient SelectionHazard ratioCancermedicine.diseaseCarboplatinmeta-analysisClinical trialTreatment Outcome030104 developmental biologyOncologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisMeta-analysisDisease ProgressionSystematic reviewFemalePersonalized medicinebusinessResearch PaperSignal Transductionmedicine.drug
researchProduct

A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis

2017

Background: The role of cortical lesions (CLs) in disease progression and clinical deficits is increasingly recognized in multiple sclerosis (MS); however the origin of CLs in MS still remains unclear. Objective: Here, we report a para-sulcal CL detected two years after diagnosis in a relapsing-remitting MS (RRMS) patient without manifestation of clinical deficit. Methods: Ultra-high field (7T) MR imaging using magnetization-prepared 2 rapid acquisition gradient echoes (MP2RAGE) sequence was performed. Results: A para-sulcal CL was detected which showed hypointense rim and iso- to hyperintense core. This was detected in the proximity of the leptomeninges in the left precentral gyrus extendi…

0301 basic medicinePathologymedicine.medical_specialty7TLesionMultiple sclerosis03 medical and health sciencesMeningeal inflammation0302 clinical medicineCLs upper limitsIn vivoatypical cortical lesionsmedicinemagnetic resonance imagingCORTICAL DEMYELINATIONmedicine.diagnostic_testbusiness.industryMultiple sclerosisDisease progressionMagnetic resonance imagingmedicine.disease030104 developmental biologyNeurologyNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Mice are not Men: ADAM30 Findings Emphasize a Broader Look Towards Murine Alzheimer's Disease Models

2016

Due to the growing population of people at advanced age, the number of patients affected by Alzheimer's disease (AD) is increasing tremendously. In 2015 about 46.8 million people suffered from AD worldwide which is estimated to increase to 131.5 million by 2050. Brains of AD patients all show a common histopathology; they are marked by an atrophy and degeneration that is caused by a severe loss of neurons and synapses (Braak and Del Tredici, 2012). Moreover, so-called extracellular senile plaques that consist of predominantly amyloid β (Aβ) peptides can be detected in the grey matter where they surround neurons. Since generation of Aβ peptides is hypothesized to play a major role in AD path…

0301 basic medicinePathologymedicine.medical_specialtyADAM10Populationlcsh:MedicineMice TransgenicGrey matterBiologyGeneral Biochemistry Genetics and Molecular BiologyPathogenesisMice03 medical and health sciences0302 clinical medicineAtrophyAlzheimer DiseasemedicineAmyloid precursor proteinAnimalsHumansSenile plaqueseducationlcsh:R5-920education.field_of_studylcsh:RP3 peptideGeneral Medicinemedicine.diseaseADAM ProteinsDisease Models Animal030104 developmental biologymedicine.anatomical_structureDisease ProgressionCommentarybiology.proteinlcsh:Medicine (General)Neuroscience030217 neurology & neurosurgeryEBioMedicine
researchProduct

Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors

2016

// Irene Tadeo 1 , Gloria Bueno 2 , Ana P. Berbegall 1 , M. Milagro Fernandez-Carrobles 2 , Victoria Castel 3 , Marcial Garcia-Rojo 4 , Samuel Navarro 1 , Rosa Noguera 1 1 Pathology Department, Medical School, University of Valencia, INCLIVA, 46010 Valencia, Spain 2 VISILAB, E.T.S. Ingenieros Industriales, University of Castilla-La Mancha, 13071 Ciudad Real, Spain 3 Pediatric Oncology Unit, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain 4 Department of Pathology, Hospital de Jerez de la Frontera, 11407 Jerez de la Frontera, Cadiz, Spain Correspondence to: Rosa Noguera Salva, e-mail: rnoguera@uv.es Keywords: extracellular matrix, blood vessels, capillaries, sinusoids, neuro…

0301 basic medicinePathologymedicine.medical_specialtyAngiogenesisextracellular matrixMalignancyMetastasisblood vesselsNeuroblastoma03 medical and health sciencesneuroblastoma0302 clinical medicinePediatric oncologyMedicineHumansTumor growthcapillariesChildsinusoidsTissue microarrayNeovascularization Pathologicbusiness.industrymedicine.diseaseNeuroblastic Tumor030104 developmental biologyOncology030220 oncology & carcinogenesisCohortDisease ProgressionbusinessResearch Paper
researchProduct

A "systems medicine" approach to the study of non-alcoholic fatty liver disease

2016

a b s t r a c t The prevalence of fatty liver (steatosis) in the general population is rapidly increasing worldwide. The progress of knowledge in the physiopathology of fatty liver is based on the systems biology approach to studying the complex interactions among different physiological systems. Similarly, translational and clinical research should address the complex interplay between these systems impacting on fatty liver. The clinical needs drive the applications of systems medicine to re-define clinical phenotypes, assessing the multiple nature of disease susceptibility and progression (e.g. the definition of risk, prognosis, diag- nosis criteria, and new endpoints of clinical trials).…

0301 basic medicinePathologymedicine.medical_specialtyFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Gastroenterology; HepatologySystems AnalysisSystems biologyPersonalizedPopulationDiseaseBioinformatics03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineFatty liverNAFLDFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicinemedicineHumansFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Hepatology; GastroenterologyeducationFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Disease Progression; Humans; Non-alcoholic Fatty Liver Disease; Phenotype; Risk Factors; Systems Biology; Systems Analysis; Medicine (all); Hepatology; Gastroenterologyeducation.field_of_studyHepatologybusiness.industrySystems BiologySettore MED/09 - MEDICINA INTERNAFatty liverGastroenterologyNASHHepatologymedicine.diseaseSystems medicineClinical trial030104 developmental biologyPhenotypeSystems medicineDisease ProgressionMedicine030211 gastroenterology & hepatologySteatosisbusiness
researchProduct

Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients

2017

International audience; T lymphoblastic lymphoma (T-LBL) is a rare type of lymphoma with a good prognosis with a remission rate of 85%. Patients can be completely cured or can relapse during or after a 2-year treatment. Relapses usually occur early after the remission of the acute phase. The median time of relapse is equal to 1 year, after the occurrence of complete remission (range 0.2–5.9 years) (Uyttebroeck et al., 2008). It can be assumed that patients may be treated longer than necessary with undue toxicity. The aim of our model was to investigate whether the duration of the maintenance therapy could be reduced without increasing the risk of relapses and to determine the minimum treatm…

0301 basic medicinePediatricsmedicine.medical_specialtymedicine.medical_treatmentPopulation[SDV.CAN]Life Sciences [q-bio]/CancerPrecursor T-Cell Lymphoblastic Leukemia-LymphomachemotherapyGeneral Biochemistry Genetics and Molecular Biology[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences[ MATH.MATH-AP ] Mathematics [math]/Analysis of PDEs [math.AP][SDV.CAN] Life Sciences [q-bio]/CancerMaintenance therapythymusT-cell lymphoblastic lymphomamedicineHumanscancer[MATH.MATH-AP]Mathematics [math]/Analysis of PDEs [math.AP]Computer Simulationmathematical modelling[MATH.MATH-AP] Mathematics [math]/Analysis of PDEs [math.AP]educationrandomized controlled clinical trialGeneral Environmental SciencePharmacologyChemotherapyeducation.field_of_studyGeneral Immunology and Microbiologybusiness.industryApplied MathematicsGeneral NeuroscienceLymphoblastic lymphomaCancerGeneral MedicineModels Theoreticalmedicine.disease3. Good healthLymphomaSurgeryClinical trial030104 developmental biologyModeling and SimulationCohortDisease ProgressionbusinessMathematical Medicine and Biology
researchProduct

3D polymeric supports promote the growth and progression of anaplastic thyroid carcinoma.

2020

Abstract Anaplastic thyroid carcinoma (ATC) is a rare and aggressive malignancy that accounts for the majority of deaths from all thyroid cancers. ATC exhibits invasiveness and highly resistance to conventional therapies which include cytotoxic chemotherapy, the combination of BRAF and MEK inhibition and, more recently, immunotherapies, that have shown promising but still limited results. A growing knowledge on ATC tumor biology is needed for developing more effective therapies with significant better survival. Researchers have begun to utilize 3D models to culture cancer cells for in vitro studies. In this work, C643 ATC cell line was cultured on polymeric scaffolds with high-interconnecte…

0301 basic medicinePolymersBiophysicsMalignancyStem cell markerThyroid Carcinoma AnaplasticBiochemistryMetastasis03 medical and health sciences0302 clinical medicineCancer stem cellCell Line TumormedicineBiomarkers TumorHumansDoxorubicin3D tumor model Anaplastic thyroid carcinoma Doxorubicin Polymeric scaffold Stem cell markersMolecular BiologyThyroid cancerCell ShapeCell ProliferationTissue Scaffoldsbusiness.industryThyroidCell Biologymedicine.disease030104 developmental biologymedicine.anatomical_structureDoxorubicin030220 oncology & carcinogenesisCancer cellCancer researchDisease ProgressionNeoplastic Stem Cellsbusinessmedicine.drugBiochemical and biophysical research communications
researchProduct